Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736633 | 0.83 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL6234986 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL4763073 | 0.83 | KDM4E (0.78) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL718439 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL28292562 | 0.82 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL8702456 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL716374 | 0.79 | RAB9A (0.65) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL7001218 | 0.77 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL6240452 | 0.77 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL5272919 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653944-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-1653944-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-7696365-B2 | Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-13 | — | — | US | disclosed |
| US-7696365-B2 | Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-13 | — | — | US | disclosed |
| US-7696365-B2 | Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-13 | — | — | US | disclosed |
| EP-1653944-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011670-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011670-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-02-10 | — | — | WO | disclosed |
| US-20050026969-A1 | Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026969-A1 | Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors | ACACA, ACACB, PC | KDM4E 878/4885ALDH1A1 270/4885SMN1; SMN2 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.